Market Overview

Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

Share:

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company
focused on the formulation, development, and commercialization of
innovative therapies for diseases and conditions of the eye, today
announced that it will present and host investor meetings at the
following conferences:

Jefferies 2019 Global Healthcare Conference
Date: Thursday,
June 6, 2019
Presentation Time: 4:30 PM ET
Location: Grand
Hyatt in New York, NY

Raymond James Life Sciences and MedTech Conference
Date:
Tuesday, June 18, 2019
Presentation Time: 4:10 PM ET
Location:
Lotte New York Palace in New York, NY

JMP Securities Life Sciences Conference
Date: Wednesday,
June 19, 2019
Presentation Time: 9:30 AM ET
Location: The St.
Regis in New York, NY

A live webcast of the presentations can be accessed by visiting the
Investors section of the Company's website at investors.ocutx.com.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc.
is a biopharmaceutical company focused on the formulation, development,
and commercialization of innovative therapies for diseases and
conditions of the eye using its proprietary bioresorbable hydrogel-based
formulation technology. Ocular Therapeutix's first commercial drug
product, DEXTENZA®, is FDA-approved for the treatment of
ocular pain following ophthalmic surgery. OTX-TP (intracanalicular
travoprost insert) is an intracanalicular insert in Phase 3 clinical
development for the reduction of intraocular pressure in patients with
primary open-angle glaucoma and ocular hypertension. The Company's
earlier stage assets include OTX-TIC, an extended-delivery intracameral
travoprost implant for the reduction of intraocular pressure in patients
with glaucoma and ocular hypertension, as well as sustained release
intravitreal implants for the treatment of retinal diseases. These
intravitreal implants include OTX-TKI, containing a tyrosine kinase
inhibitor (TKI), and, in collaboration with Regeneron, OTX-IVT, an
extended-delivery protein-based anti-vascular endothelial growth factor
(VEGF) trap. Ocular Therapeutix's first product, ReSure®
Sealant, is FDA-approved to seal corneal incisions following cataract
surgery.

View Comments and Join the Discussion!
 
Lightning Fast
Market News Service
$199 Free 14 Day Trial